Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27883988 | 0.76 | HSPA5 (0.58) | TAAR1DAO | |
| SCHEMBL20117714 | 0.76 | DAO (0.49) | TAAR1ARP2RX7ALDH1A1DAO | |
| SCHEMBL20117768 | 0.76 | IDO1 (0.46) | TAAR1ARALDH1A1 | |
| SCHEMBL79201 | 0.75 | MAOA (0.47) | MAOADAO | |
| SCHEMBL2090458 | 0.75 | TAAR1 (0.56) | TAAR1ARP2RX7ALDH1A1HPGD | |
| SCHEMBL29477327 | 0.75 | TAAR1 (0.56) | TAAR1ARP2RX7ALDH1A1HPGD | |
| SCHEMBL28180473 | 0.73 | ADRA2A (0.58) | TAAR1ALDH1A1HPGDLMNA | |
| SCHEMBL27647904 | 0.73 | DPP4 (0.47) | MAOA | |
| SCHEMBL11200954 | 0.73 | TAAR1 (0.54) | TAAR1ARP2RX7ALDH1A1HPGD | |
| SCHEMBL6284681 | 0.73 | MAOA (0.45) | MAOADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS | 2022-01-27 | — | — | US | disclosed |
| US-10975030-B2 | Grp94 selective inhibitors and uses thereof | UNIVERSITY OF KANSAS (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200071271-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2020-03-05 | — | — | US | disclosed |
| WO-2018081814-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071271-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | GRPR, HSP90B1, HSPE1 | TAAR1 2540/4885MAOA 4630/4885AR 3307/4885 |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | GRPR, HSP90B1, HSPE1 | TAAR1 2540/4885MAOA 4630/4885AR 3307/4885 |
| US-10975030-B2 | Grp94 selective inhibitors and uses thereof | GRPR, HSP90B1, HSPE1 | TAAR1 2540/4885MAOA 4630/4885AR 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.